Literature DB >> 23897275

Responsiveness to change and interpretability of the simplified psoriasis index.

Leena Chularojanamontri1, Christopher E M Griffiths2, Robert J G Chalmers3.   

Abstract

The Simplified Psoriasis Index (SPI) is a summary measure of psoriasis with separate components for current severity (weighted for functionally or psychosocially important sites), psychosocial impact, and past behavior. The current severity components of the professionally assessed SPI (proSPI-s) and self-assessed SPI (saSPI-s) have each been shown to be valid and reliable. Their responsiveness to change and equivalence to the current standard (Psoriasis Area and Severity Index, PASI) were investigated. Responsiveness and minimum clinically important differences (MCIDs) were derived from PASI changes from baseline at weeks 4 (n=100) and 10 (n=65) in patients commencing therapy for psoriasis. Receiver operating characteristic (ROC) analysis confirmed that both measures detected responsiveness well (area under the curve (AUC)=0.72-0.96). On ROC and PASI-based anchor analysis, MCIDs equated to mean absolute and percentage changes of 5 and 60% (proSPI-s), and 7 and 70% (saSPI-s). Satisfactory response as defined by 75% reduction in PASI equated to 85 and 95% reductions in proSPI-s and saSPI-s, respectively. PASI-equivalent cutoff scores for mild (PASI<10) and severe (PASI>20) psoriasis were <9 and >18 for proSPI-s (n=300) and <10 and >20 for saSPI-s (n=200; AUC=0.86-0.96). These studies further support the validity of SPI for use in routine clinical practice.

Entities:  

Mesh:

Year:  2013        PMID: 23897275     DOI: 10.1038/jid.2013.318

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  18 in total

1.  Validation of psoriasis clinical severity and outcome measures: searching for a gold standard.

Authors:  J Daniel Jensen; Mayumi Fujita; Robert P Dellavalle
Journal:  Arch Dermatol       Date:  2010-09-20

2.  Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal.

Authors:  Kenneth A Katz
Journal:  J Am Acad Dermatol       Date:  2005-09       Impact factor: 11.527

Review 3.  Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.

Authors:  Dennis Revicki; Ron D Hays; David Cella; Jeff Sloan
Journal:  J Clin Epidemiol       Date:  2007-08-03       Impact factor: 6.437

4.  Using the entire cohort in the receiver operating characteristic analysis maximizes precision of the minimal important difference.

Authors:  Dan Turner; Holger J Schünemann; Lauren E Griffith; Dorcas E Beaton; Anne M Griffiths; Jeffrey N Critch; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2008-11-14       Impact factor: 6.437

5.  The minimal detectable change cannot reliably replace the minimal important difference.

Authors:  Dan Turner; Holger J Schünemann; Lauren E Griffith; Dorcas E Beaton; Anne M Griffiths; Jeffrey N Critch; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2009-10-01       Impact factor: 6.437

6.  Infliximab for the treatment of adults with psoriasis.

Authors:  E Loveman; D Turner; D Hartwell; K Cooper; A Clegg
Journal:  Health Technol Assess       Date:  2009-06       Impact factor: 4.014

7.  Minimal change is sensitive, less specific to recovery: a diagnostic testing approach to interpretability.

Authors:  Dorcas E Beaton; Dwayne van Eerd; Peter Smith; Gabrielle van der Velde; Kimberley Cullen; Carol A Kennedy; Sheilah Hogg-Johnson
Journal:  J Clin Epidemiol       Date:  2010-12-15       Impact factor: 6.437

Review 8.  Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies.

Authors:  Luigi Naldi
Journal:  Clin Dermatol       Date:  2010 Jan-Feb       Impact factor: 3.541

9.  The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content.

Authors:  Lidwine B Mokkink; Caroline B Terwee; Dirk L Knol; Paul W Stratford; Jordi Alonso; Donald L Patrick; Lex M Bouter; Henrica Cw de Vet
Journal:  BMC Med Res Methodol       Date:  2010-03-18       Impact factor: 4.615

10.  Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors.

Authors:  Cecilia A C Prinsen; Robert Lindeboom; Mirjam A G Sprangers; Catharina M Legierse; John de Korte
Journal:  J Invest Dermatol       Date:  2009-12-24       Impact factor: 8.551

View more
  7 in total

1.  Assessing the validity and interpretability of the Simplified Psoriasis Index in Tunisian patients.

Authors:  Ines Chabchoub; Noureddine Litaiem; Soumaya Gara; Kahena Jaber; Mohamed Abderraouf Dhaoui; Faten Zeglaoui
Journal:  Tunis Med       Date:  2022 Janvier

2.  Translation and validation of the Simplified Psoriasis Index (SPI) into Brazilian Portuguese.

Authors:  Marina Resener de Morais; Gladys Aires Martins; Ricardo Romiti; Renata Elise Tonoli; André Vicente Esteves Carvalho
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

Review 3.  Measuring Outcomes in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura C Coates; Philip Mease
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

4.  Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis.

Authors:  Edoardo Pasolli; Stefania Farina; Duy Tin Truong; Adrian Tett; Francesco Asnicar; Moreno Zolfo; Francesco Beghini; Federica Armanini; Olivier Jousson; Veronica De Sanctis; Roberto Bertorelli; Giampiero Girolomoni; Mario Cristofolini; Nicola Segata
Journal:  NPJ Biofilms Microbiomes       Date:  2017-06-22       Impact factor: 7.290

5.  Patient-Reported Disease Severity and Quality of Life Among Arabic Psoriatic Patients: A Cross-Sectional Survey.

Authors:  Moetaza Soliman
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-08-25

Review 6.  The Meaning and Reliability of Minimal Important Differences (MIDs) for Clinician-Reported Outcome Measures (ClinROMs) in Dermatology-A Scoping Review.

Authors:  Reinhart Speeckaert; Arno Belpaire; Sandrine Herbelet; Marijn M Speeckaert; Nanja van Geel
Journal:  J Pers Med       Date:  2022-07-18

7.  Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study.

Authors:  M-A Richard; J-P Lacour; M-P Konstantinou; M Ruer-Mulard; P Joly; S Aractingi; P Auquier; B Pelvet; M L Augustin; E Mahé; R J G Chalmers
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-10-02       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.